X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
animals (4) 4
mice (4) 4
benzamides (3) 3
chronic myelogenous leukemia (3) 3
chronic myeloid-leukemia (3) 3
imatinib mesylate (3) 3
medicine, research & experimental (3) 3
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
calcium - metabolism (2) 2
cancer (2) 2
cell biology (2) 2
cell death - drug effects (2) 2
cell line, tumor (2) 2
cells, cultured (2) 2
corrigendum (2) 2
dasatinib (2) 2
fusion proteins, bcr-abl (2) 2
hematology (2) 2
immunohistochemistry (2) 2
index medicus (2) 2
israel (2) 2
male (2) 2
mice, inbred c3h (2) 2
mutation (2) 2
obstetrics and gynecology (2) 2
piperazines - pharmacology (2) 2
protein-tyrosine kinases - antagonists & inhibitors (2) 2
pyrimidines - pharmacology (2) 2
rna interference (2) 2
xenograft model antitumor assays (2) 2
20. století (1) 1
3t3 cells (1) 1
abl tyrosine kinase (1) 1
abridged index medicus (1) 1
adenosine triphosphatases - analysis (1) 1
adenosine triphosphatases - metabolism (1) 1
adjuvant chemotherapy (1) 1
adolescent (1) 1
adolescents (1) 1
alanine - genetics (1) 1
alanine - metabolism (1) 1
alcoholism - epidemiology (1) 1
alcoholism - psychology (1) 1
alkaline phosphatase - biosynthesis (1) 1
american society (1) 1
amino acid sequence - genetics (1) 1
amphiregulin (1) 1
antigens, cd20 - metabolism (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - toxicity (1) 1
architecture (1) 1
architecture israël 20e siècle (1) 1
architecture urbaine (1) 1
architektonické práce (1) 1
architektonické řešení města (1) 1
architektura (1) 1
ascorbic acid - pharmacology (1) 1
automated pcr detection (1) 1
autophagy (1) 1
autophagy - drug effects (1) 1
autophagy - physiology (1) 1
autopsy (1) 1
bcr-abl mutations (1) 1
binding sites (1) 1
binding sites - genetics (1) 1
blast crisis (1) 1
bouwkunst (1) 1
buildings, structures, etc (1) 1
c-abl (1) 1
calcification, physiologic - drug effects (1) 1
calcium (1) 1
caractère national (1) 1
carcinoma (1) 1
cardiovascular disease (1) 1
caspase activation (1) 1
casualties (1) 1
catalytic domain - drug effects (1) 1
catalytic domain - genetics (1) 1
causes of (1) 1
cell adhesion molecules - metabolism (1) 1
cell death (1) 1
cell death - physiology (1) 1
cell division - physiology (1) 1
cell membrane permeability - drug effects (1) 1
cell transformation, neoplastic - genetics (1) 1
cell transformation, neoplastic - metabolism (1) 1
cementogenesis (1) 1
cetuximab (1) 1
chemotherapy (1) 1
chloroquine (1) 1
chloroquine - pharmacology (1) 1
chloroquine - therapeutic use (1) 1
chronic myeloid leukemia (1) 1
city planning (1) 1
cladribine (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2006, Volume 12, Issue 8, pp. 908 - 916
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten... 
CHRONIC MYELOGENOUS LEUKEMIA | ADJUVANT CHEMOTHERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | C-ABL | ABL TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | N-TERMINAL KINASE | NEURONAL CELL-DEATH | ENDOPLASMIC-RETICULUM STRESS | HER2-POSITIVE BREAST-CANCER | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | UNFOLDED PROTEIN RESPONSE | Mitochondria, Heart - ultrastructure | Piperazines - administration & dosage | Calcium - metabolism | Mitochondria, Heart - pathology | Sarcoplasmic Reticulum - drug effects | Humans | Piperazines - toxicity | Antineoplastic Agents - administration & dosage | Mitochondria, Heart - drug effects | Ventricular Dysfunction, Left - chemically induced | Antineoplastic Agents - toxicity | Dose-Response Relationship, Drug | Mitochondrial Membranes - drug effects | Pyrimidines - toxicity | Time Factors | Adenosine Triphosphatases - analysis | Antineoplastic Agents - adverse effects | Sarcoplasmic Reticulum - ultrastructure | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Membrane Potentials - drug effects | Severity of Illness Index | Cytochromes c - secretion | Echocardiography | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Cells, Cultured | Injections, Intraperitoneal | Adenosine Triphosphatases - metabolism | Heart Failure - pathology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - adverse effects | Piperazines - pharmacology | Ventricular Dysfunction, Left - physiopathology | Myocytes, Cardiac - pathology | Animals | Myocytes, Cardiac - drug effects | Cell Membrane Permeability - drug effects | Pyrimidines - adverse effects | Sarcoplasmic Reticulum - pathology | Mice | Benzamides | Myocytes, Cardiac - ultrastructure | Heart Failure - chemically induced | Heart failure | Chemotherapy | Side effects | Inhibitor drugs | Toxicity | Cardiovascular disease | Cancer
Journal Article
Journal of Affective Disorders, ISSN 0165-0327, 08/2018, Volume 235, pp. 341 - 347
Journal Article
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2015, Volume 212, Issue 1, pp. S261 - S261
Journal Article
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2014, Volume 210, Issue 1, pp. S276 - S276
Journal Article
Molecular Cell, ISSN 1097-2765, 2003, Volume 12, Issue 1, pp. 27 - 37
Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like C-Abl, Bcr-Abl is negatively regulated... 
TYROSINE KINASE-ACTIVITY | CHRONIC MYELOGENOUS LEUKEMIA | TRANSFORMATION | OLIGOMERIZATION DOMAIN | REGULATES C-ABL | GROWTH-FACTOR INDEPENDENCE | PHILADELPHIA-CHROMOSOME | BIOCHEMISTRY & MOLECULAR BIOLOGY | FAMILY KINASES | INHIBITOR | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | Catalytic Domain - drug effects | Protein Binding - genetics | Proline - metabolism | Protein-Tyrosine Kinases - metabolism | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Amino Acid Sequence - genetics | Proline - genetics | Protein-Tyrosine Kinases - genetics | Alanine - genetics | Fusion Proteins, bcr-abl | Cell Transformation, Neoplastic - genetics | Protein Binding - drug effects | Phosphorylation - drug effects | Eukaryotic Cells - enzymology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Catalytic Domain - genetics | Enzyme Inhibitors - pharmacology | Models, Molecular | Alanine - metabolism | Protein Structure, Tertiary - genetics | Binding Sites - genetics | Mutation - genetics | Cell Transformation, Neoplastic - metabolism | Tyrosine - metabolism | Animals | Mutation - drug effects | Feedback, Physiological - genetics | Feedback, Physiological - drug effects | Mice | Mice, Inbred BALB C | 3T3 Cells | Protein Structure, Tertiary - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article
2004, Design and the built environment series, ISBN 0754634272, xiii,356
Book
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.